ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE
Clinical trials for ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE explained in plain language.
Never miss a new study
Get alerted when new ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE trials appear
Sign up with your email to follow new studies for ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising new combo therapy for infant leukemia shows potential
Disease control Recruiting nowThis study tests whether adding two targeted drugs, blinatumomab and venetoclax, to standard chemotherapy can improve outcomes for infants with a type of leukemia called acute lymphoblastic leukemia (ALL). About 153 infants will participate. The goal is to see if these combinatio…
Matched conditions: ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
Could removing certain immune cells prevent a deadly transplant complication?
Disease control Recruiting nowThis study tests whether removing a specific type of immune cell (naive T cells) from donor stem cells can prevent chronic graft-versus-host disease (GVHD) in children and young adults with blood cancers. GVHD occurs when donor cells attack the patient's body after a stem cell tr…
Matched conditions: ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for kids with relapsed leukemia: experimental drug combo enters safety trial
Disease control Recruiting nowThis early-stage study tests whether adding a new drug called revumenib to two standard chemotherapy drugs is safe for children and young adults whose acute myeloid leukemia (AML) has not responded to treatment or has returned. The study involves 24 participants and aims to find …
Matched conditions: ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Second chance: cord blood transplant trial for relapsed blood cancers
Disease control Recruiting nowThis phase 2 trial tests an optimized cord blood transplant for 35 patients with high-risk blood cancers (like leukemia) who relapsed after their first stem cell transplant. Participants receive chemotherapy followed by a cord blood infusion, plus drugs to prevent rejection. The …
Matched conditions: ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New hope for kids with tough leukemia: drug combo enters human testing
Disease control Recruiting nowThis early-stage trial is testing whether adding the drug talazoparib to standard chemotherapy is safe for children and young adults up to age 21 whose acute myeloid leukemia (AML) has returned or not responded to treatment. About 34 participants will receive different doses to f…
Matched conditions: ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE
Phase: PHASE1 • Sponsor: Norman J. Lacayo • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for Hard-to-Treat leukemia? enzomenib trial launches
Disease control Recruiting nowThis study tests a new oral drug called enzomenib (DSP-5336) in people with acute leukemia and certain other blood cancers that have not responded to standard treatments. The trial has two phases: first, finding the safest dose, and then checking how well it works alone or combin…
Matched conditions: ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE
Phase: PHASE1, PHASE2 • Sponsor: Sumitomo Pharma America, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New hope for tough leukemias: experimental pill targets genetic weakness
Disease control Recruiting nowThis study tests an oral drug called revumenib in people with certain types of leukemia that have relapsed or not responded to standard therapy. The trial has two parts: first, finding the best dose, then testing that dose in four groups based on leukemia type. About 447 particip…
Matched conditions: ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE
Phase: PHASE1, PHASE2 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New hope for tough blood cancers: venetoclax combo enters human trials
Disease control Recruiting nowThis early-phase trial is testing whether adding the drug venetoclax to standard chemotherapy is safe and tolerable for children, adolescents, and young adults with high-risk blood cancers like MDS, AML, and ALL. About 30 participants will receive different combinations of chemot…
Matched conditions: ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE
Phase: PHASE1 • Sponsor: Andrew E. Place, MD • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug aims to keep leukemia away after transplant
Disease control Recruiting nowThis early-phase trial tests a drug called revumenib in people with acute leukemia who have had a stem cell transplant. The drug targets a protein that helps leukemia cells grow. The study will check safety, find the best dose, and see if it can stop the cancer from coming back. …
Matched conditions: ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New hope for tough leukemia cases: drug combo trial opens for kids and young adults
Disease control Recruiting nowThis study is for children, teens, and young adults (ages 1 to 39) with acute leukemia that has come back or not gotten better with standard treatments. Researchers are testing whether combining two drugs—venetoclax and Vyxeos—is safe and tolerable. The goal is to find the best d…
Matched conditions: ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE
Phase: PHASE1 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New hope for older AML patients: shorter, safer transplant strategy
Disease control Recruiting nowThis pilot study tests a new treatment plan for adults aged 60 and older with high-risk acute myeloid leukemia (AML) or similar blood cancers. The plan combines a strong chemotherapy regimen (FLAG-Ida) with a lower-intensity stem cell transplant just a few days later. The goal is…
Matched conditions: ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for kids with tough leukemias: experimental combo trial opens
Disease control Recruiting nowThis phase 1 study is testing a combination of three drugs—ziftomenib, venetoclax, and azacitidine—in children and young adults (ages 2 to 21) with acute leukemia that has returned or not responded to treatment. The main goal is to find the safest dose of ziftomenib when given wi…
Matched conditions: ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New cord blood transplant method aims to beat high-risk blood cancers
Disease control Recruiting nowThis study tests a special cord blood transplant for people with high-risk blood cancers like leukemia and lymphoma. Participants get chemotherapy and radiation before the transplant to kill cancer cells and prepare the body. After the transplant, drugs are given to prevent the n…
Matched conditions: ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New combo therapy shows promise for rare, Tough-to-Treat leukemia
Disease control Recruiting nowThis phase 2 trial is testing whether combining venetoclax and azacitidine can help people with a rare type of leukemia called acute leukemia of ambiguous lineage. The study will enroll 23 newly diagnosed patients aged 15 and older. The goal is to see if this drug combination can…
Matched conditions: ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE
Phase: PHASE2 • Sponsor: Sheng-Li Xue, MD • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New cord blood transplant recipe aims to beat tough blood cancers
Disease control Recruiting nowThis study tests a standardized, optimized approach to cord blood transplantation for adults with high-risk blood cancers like leukemia and lymphoma. The method includes specific chemotherapy, radiation, and stem cell dosing, followed by careful monitoring. Researchers hope to im…
Matched conditions: ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 26, 2026 15:21 UTC
-
Can talk therapy and symptom tracking ease the trauma of leukemia?
Symptom relief Recruiting nowThis study tests a program called EASE that combines psychological support with regular symptom checks and early access to palliative care. Researchers want to see if it reduces traumatic stress and physical symptoms in people newly diagnosed with acute leukemia. Half of the 266 …
Matched conditions: ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE
Phase: NA • Sponsor: Canadian Cancer Trials Group • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Coin flip chemo: study tests if patients will let a computer choose their treatment strength
Knowledge-focused Recruiting nowThis study looks at whether adults with acute myeloid leukemia (AML) who are not healthy enough for strong chemotherapy are willing to let a computer randomly assign them to either lower- or higher-intensity treatment. The goal is to see if this approach is acceptable to patients…
Matched conditions: ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE
Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC